This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Charles River, Lilly TuneLab Collaborate
Business collaboration

Charles River, Lilly TuneLab Collaborate

Analysis based on 6 articles · First reported Jun 18, 2026 · Last updated Jun 18, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The collaboration between Charles River Laboratories International, Inc. and Eli Lilly and Company's Lilly TuneLab is expected to positively impact the biotechnology and pharmaceutical sectors by accelerating drug discovery and development through AI/ML models and nonclinical testing. This could lead to faster market entry for new therapeutics, benefiting both companies and the broader healthcare market.

Biotechnology Pharmaceuticals Artificial intelligence
Event Summary

Charles River Laboratories International, Inc. announced a collaboration with Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly and Company. Through this partnership, Charles River Laboratories International, Inc. will provide nonclinical testing services to companies participating in Lilly TuneLab. The goal is to accelerate biotech innovation by combining Charles River Laboratories International, Inc.'s expertise in nonclinical testing with Lilly TuneLab's AI/ML models, which are trained on Eli Lilly and Company's proprietary research data. This initiative aims to streamline the down-selection of candidate molecules and improve the efficiency of drug development, ultimately leading to faster access to life-saving treatments.

Entities Involved
stock
Charles River Laboratories
Charles River Laboratories International, Inc. is collaborating with Lilly TuneLab to provide nonclinical testing services, which is expected to accelerate drug development and modernize R&D through innovative technologies.
Importance 100.0 Sentiment 60.0
oth
Lilly TuneLab
Lilly TuneLab is an AI/ML drug discovery platform created by Eli Lilly and Company that will benefit from Charles River Laboratories International, Inc.'s nonclinical testing services to accelerate therapeutic development.
Importance 90.0 Sentiment 60.0
per
Namandje N. Bumpus
Dr. Namandj N. Bumpus, Chief Science and Innovation Officer at Charles River Laboratories International, Inc., commented on the collaboration's benefits for accelerating innovative therapeutics.
Importance 30.0 Sentiment 50.0
oth
Lilly Catalyze360
Lilly TuneLab is part of Lilly Catalyze360, which supports biotech innovation by providing access to strategic capital, lab space, and technology.
Importance 20.0 Sentiment 50.0
oth
Alternative Methods Advancement Project
The Alternative Methods Advancement Project (AMAP) is a Charles River-led initiative focused on developing New Approach Methodologies (NAMs) to reduce reliance on traditional animal testing, aligning with the broader goals of accelerating drug development.
Importance 20.0 Sentiment 50.0
stock
Eli Lilly and Company
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.